MedTrace Logo

Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects

NCT05468060 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-07-21

No results posted yet for this study

Summary

The primary objectives of this study are to evaluate the safety, tolerability and pharmacokinetics characteristics of single ascending dose (SAD) of PA1010 tablets in Chinese healthy adults and the impact of food and gender on the pharmacokinetics

Conditions

  • Chronic HBV Infection

Interventions

DRUG

PA1010

Placebo as control

Sponsors & Collaborators

  • Zhejiang Palo Alto Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Xuebing Yan, MD · The Affiliated Hospital of Xuzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-28
Primary Completion
2020-12-12
Completion
2020-12-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05468060 on ClinicalTrials.gov